tetano
Editor, Senior Moderator
Cell Rep
. 2021 Dec 21;110237.
doi: 10.1016/j.celrep.2021.110237. Online ahead of print.
High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
Takuya Tada[SUP] 1 [/SUP], Hao Zhou[SUP] 1 [/SUP], Belinda M Dcosta[SUP] 1 [/SUP], Marie I Samanovic[SUP] 2 [/SUP], Amber Cornelius[SUP] 2 [/SUP], Ramin S Herati[SUP] 2 [/SUP], Mark J Mulligan[SUP] 2 [/SUP], Nathaniel R Landau[SUP] 3 [/SUP]
Affiliations
Abstract
Recently identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants Mu and C.1.2 have spike proteins with mutations that may confer resistance to natural and vaccine-elicited antibodies. Analysis of neutralizing antibody titers in the sera of vaccinated individuals without previous history of infection and from convalescent individuals show partial resistance of the viruses. In contrast, sera from individuals with a previous history of SARS-CoV-2 infection who were subsequently vaccinated neutralize variants with titers 4- to 11-fold higher, providing a rationale for vaccination of individuals with previous infection. The heavily mutated C.1.2 spike is the most antibody neutralization-resistant spike to date; however, the avidity of C.1.2 spike protein for angiotensin-converting enzyme 2 (ACE2) is low. This finding suggests that the virus evolved to escape the humoral response but has a decrease in fitness, suggesting that it may cause milder disease or be less transmissible. It may be difficult for the spike protein to evolve to escape neutralizing antibodies while maintaining high affinity for ACE2.
Keywords: ACE2; Ad26.COV2.S; C.1.2; COVID-19; Moderna mRNA-1273; Mu; Pfizer BNT162b2; SARS-CoV-2; antibodies; vaccine.
. 2021 Dec 21;110237.
doi: 10.1016/j.celrep.2021.110237. Online ahead of print.
High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
Takuya Tada[SUP] 1 [/SUP], Hao Zhou[SUP] 1 [/SUP], Belinda M Dcosta[SUP] 1 [/SUP], Marie I Samanovic[SUP] 2 [/SUP], Amber Cornelius[SUP] 2 [/SUP], Ramin S Herati[SUP] 2 [/SUP], Mark J Mulligan[SUP] 2 [/SUP], Nathaniel R Landau[SUP] 3 [/SUP]
Affiliations
- PMID: 34982967
- DOI: 10.1016/j.celrep.2021.110237
Abstract
Recently identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants Mu and C.1.2 have spike proteins with mutations that may confer resistance to natural and vaccine-elicited antibodies. Analysis of neutralizing antibody titers in the sera of vaccinated individuals without previous history of infection and from convalescent individuals show partial resistance of the viruses. In contrast, sera from individuals with a previous history of SARS-CoV-2 infection who were subsequently vaccinated neutralize variants with titers 4- to 11-fold higher, providing a rationale for vaccination of individuals with previous infection. The heavily mutated C.1.2 spike is the most antibody neutralization-resistant spike to date; however, the avidity of C.1.2 spike protein for angiotensin-converting enzyme 2 (ACE2) is low. This finding suggests that the virus evolved to escape the humoral response but has a decrease in fitness, suggesting that it may cause milder disease or be less transmissible. It may be difficult for the spike protein to evolve to escape neutralizing antibodies while maintaining high affinity for ACE2.
Keywords: ACE2; Ad26.COV2.S; C.1.2; COVID-19; Moderna mRNA-1273; Mu; Pfizer BNT162b2; SARS-CoV-2; antibodies; vaccine.